SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pharmaids Pharma - Quaterly Results

07 Aug 2025 Evaluate
The total revenue stands at Rs. 11.15 millions for the June 2025 quarter. The mentioned figure indicates an increase of about 571.69% as against Rs. 1.66 millions during  the year-ago period.The Net Loss for the quarter ended June 2025 is Rs. -43.63 millions as compared to Net Loss of Rs. -16.24 millions of corresponding quarter ended June 2024 Operating profit Margin for the quarter ended June 2025 further decreased to -45.29% as compared to -17.14% of corresponding quarter ended June 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 11.15 1.66 571.69 11.15 1.66 571.69 23.41 0.28 8260.71
Other Income 3.47 0.03 11466.67 3.47 0.03 11466.67 10.19 7.95 28.18
PBIDT -45.29 -17.14 164.24 -45.29 -17.14 164.24 -62.38 -55.76 11.87
Interest 11.11 0.13 8446.15 11.11 0.13 8446.15 21.49 3.33 545.35
PBDT -56.40 -17.27 226.58 -56.40 -17.27 226.58 -83.87 -59.09 41.94
Depreciation 0.51 0.48 6.25 0.51 0.48 6.25 2.00 1.77 12.99
PBT -56.91 -17.75 220.62 -56.91 -17.75 220.62 -85.87 -60.86 41.09
TAX -13.28 -1.51 779.47 -13.28 -1.51 779.47 -13.08 -11.37 15.04
Deferred Tax -13.28 -1.51 779.47 -13.28 -1.51 779.47 -13.08 -11.37 15.04
PAT -43.63 -16.24 168.66 -43.63 -16.24 168.66 -72.79 -49.49 47.08
Equity 352.68 352.68 0.00 352.68 352.68 0.00 352.68 352.68 0.00
PBIDTM(%) -406.19 -1032.53 -60.66 -406.19 -1032.53 -60.66 -266.47 -19914.29 -98.66

Pharmaids Pharma Share Price

30.92 -0.49 (-1.56%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×